TC BioPharm is letting go around 20 employees, or approximately half of its headcount, in line with its push to become a “leaner and more agile” company with a more decentralized model. The workforce reduction is part of a larger shift within the company toward a CDMO model, allowing it to respond to larger production demands for future trials, as well as giving it the opportunity to look for alternative manufacturing facilities that can incorporate more advanced technologies. The layoffs will mostly affect employees in the company’s production and quality units and will be “substantially complete” by the end of the second quarter.